✉news HealthMedicine first seen 19 h ago, last 19 h ago, peak #32
Lu-177 FAP-2286 shows control of lung cancer brain metastases
Original: Lu-177 FAP-2286 controls lung cancer brain metastases
The radiopharmaceutical Lu-177 FAP-2286, which targets fibroblast activation protein, is reported to control brain metastases in lung cancer patients. The findings suggest the targeted radionuclide therapy can deliver radiation effectively to tumors in the brain, a site historically difficult to treat. It is being discussed in nuclear medicine and oncology circles as a promising development for a patient group with limited options.
Why now: New clinical evidence suggests a targeted radioligand therapy can treat brain metastases from lung cancer, an area of high unmet need.
Lu-177 FAP-2286lung cancerbrain metastases
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/4925039